CN109498731A - 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 - Google Patents
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 Download PDFInfo
- Publication number
- CN109498731A CN109498731A CN201811603562.XA CN201811603562A CN109498731A CN 109498731 A CN109498731 A CN 109498731A CN 201811603562 A CN201811603562 A CN 201811603562A CN 109498731 A CN109498731 A CN 109498731A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- tonifying
- pill
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 50
- 210000003734 kidney Anatomy 0.000 title claims abstract description 49
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 34
- 239000006187 pill Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000009636 Huang Qi Substances 0.000 claims abstract description 25
- 241000209020 Cornus Species 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- 239000011148 porous material Substances 0.000 claims abstract description 21
- 239000006071 cream Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 63
- 239000000463 material Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 5
- 238000005498 polishing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 229940126678 chinese medicines Drugs 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 31
- 239000008280 blood Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 230000035619 diuresis Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000026475 palpebral edema Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 208000008967 Enuresis Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010016029 Face oedema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,公开了一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法,原料包括:太子参、山萸肉、生山药、生地、泽泻、猪苓、茯苓、黄芪、苍术、白术、川牛膝、怀牛膝、升麻和枳壳。制备方法为:将太子参、山萸肉、生山药、生地、泽泻、猪苓和茯苓烘干,混合后粉碎成细粉。将黄芪、苍术、白术、川牛膝、怀牛膝、升麻和枳壳加水煎煮,煎液滤过,滤液浓缩至清膏,与细粉混合拌膏后挤压制丸,抛光干燥。本发明的健脾益肾调糖丸无毒无副作用,具有健脾益肾之功效,用于治疗2型糖尿病脾肾气虚证。
Description
技术领域
本发明涉及中药领域,具体涉及一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法。
背景技术
糖尿病是一种以高血糖为特征的代谢性疾病,高血糖则是由于胰岛素分泌缺陷或是其他生物作用受损,或两者兼有引起。中国是糖尿病大国,其糖尿病人绝对数一直以来都是全球之冠,2010年中国成人糖尿病率已经超过11%,因此必须引起高度重视。糖尿病分为1型糖尿病和2型糖尿病。1型糖尿病发病年龄轻,多发生于青少年,临床表现为起病突然,且多饮多尿多食体重减轻的症状明显,胰岛素分泌不足,机体必须依赖外源性胰岛素生存。2型糖尿病常见于老年人,肥胖者发病率高,常可伴有高血压、血脂异常和动脉硬化等疾病。在糖尿病患者中,2型糖尿病所占的比例是95%。
目前临床治疗2型糖尿病多为西药,口服药物治疗包括磺酰脲类药物、非磺酰脲类胰岛素促分泌剂、双胍类降糖药和糖苷酶抑制剂等,降糖作用明显,但副作用也很多,主要不良反应有恶心、头痛、腹痛、乳酸中毒等,且对严重肝、肾功能不全患者以及孕妇来说是禁忌。注射类药物如胰岛素则不方便随身携带及使用,且长期使用易出现低血糖、体重增加、水肿等副作用。
相比于西药治疗,中医药治疗糖尿病历史悠久,糖尿病属于中医“消渴”范畴。早在公元前四世纪《黄帝内经》一书中就有记载。《素文·气厥论》有“肺消者饮一溲一,死不治”记载。《黄帝内经》还依据不同的病因病机及临床症状,分别提出“消渴”、“消瘅”、“肺消”、“鬲消”、“消中”等病名。现代中医对消渴症的辩证论治,主要是借鉴古代医家治疗消渴病的验方而化裁。目前治疗糖尿病的中医药配方层出不穷,但效果不尽如人意。
申请号为201510690480.3的专利文件公开了一种治疗糖尿病的药物,其药物由人参、黄芪、何首乌、黄精等34种药材制成。但由于其药材种类繁多,药效却并没有得到更大的提升,反而使得制作过程繁琐、治疗费用高。
申请号为201611038017.1的专利文件公布了一种糖尿病用中药,其缺点在于所制药物为外用,使得药物的效果不能完全被机体所吸收,药物利用率不高。
发明内容
为解决上述问题,本发明提出了一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法。该药物由13种纯中药配制,制作简单,并且治疗糖尿病脾肾气虚证效果显著。
本发明提供以下技术方案:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,采用以下中药原料制备而成:太子参125~135g、山萸肉120~135g、生山药120~135g、生地120~135g、泽泻115~125g、猪苓115~125g、茯苓115~125g、黄芪190~210g、苍术40~55g、白术40~45g、川牛膝115~125g、怀牛膝115~125g、升麻25~35g和枳壳40~50g。
进一步地,采用以下中药原料制备而成:太子参125g、山萸肉120g、生山药120g、生地120g、泽泻115g、猪苓115g、茯苓115g、黄芪190g、苍术40g、白术40g、川牛膝115g、怀牛膝115g、升麻25g和枳壳40g。
进一步地,采用以下中药原料制备而成:太子参130g、山萸肉127g、生山药127g、生地127g、泽泻120g、猪苓120g、茯苓120g、黄芪200g、苍术47g、白术43g、川牛膝120g、怀牛膝120g、升麻30g和枳壳45g。
进一步地,采用以下中药原料制备而成:太子参135g、山萸肉135g、生山药135g、生地135g、泽泻125g、猪苓125g、茯苓125g、黄芪210g、苍术55g、白术45g、川牛膝125g、怀牛膝125g、升麻40g和枳壳50g。
本发明还提供一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸的制备方法,包括以下步骤:
A.将太子参、山萸肉、生山药、生地、泽泻、猪苓和茯苓放入烘箱,75℃烘干12小时,混合均匀后粉碎成80目细粉备用;
B.将黄芪、苍术、白术、川牛膝、怀牛膝、升麻和枳壳加适量的水煎煮三次,煎液合并滤过,滤液浓缩至清膏;
C.将步骤A所制细粉与步骤B所制清膏混合后挤压制丸,抛光干燥即得。
进一步地,煎煮三次中第一次煎煮为2小时,第二次煎煮和第三次煎煮均为1小时。
本发明中药物的药理作用:
太子参:味甘、微苦;性平。归脾、肺经。益气健脾,生津润肺。用于脾虚体倦,食欲不振,病后虚弱,气阴不足,自汗口渴,肺燥干咳。
黄芪:味甘;性温。归肺、脾、肝、肾经。补气升阳,益卫固表、托毒生肌、利水退肿。用于脾胃虚弱、食少倦怠,气虚血脱。
山萸肉:味酸、涩;性温。补益肝肾,涩精止汗。用于肝肾不足之腰酸遗精、头晕目眩、月经过多以及尿频、自汗等症。
生山药:味甘;性平。补脾养胃,生津益肺,补肾涩精。用于脾虚食少、久泻不啻、肺虚咳喘、肾虚遗精、带下、尿频、虚热解渴。
生地黄:味甘苦;性寒。清热凉血,养阴生津。用于热入营血,温毒发斑,热病伤阴,舌绛烦渴,津伤便秘,阴虚发热,骨蒸劳热,内热消渴。
泽泻:味甘;性寒。归肾、膀胱经。利水,渗湿,泄热。治小便不利,水肿胀满,呕吐,泻痢,痰饮,脚气,淋病,尿血。
猪苓:味甘、淡,性平。归心、脾、胃、肺、肾经。利水渗湿。治小便不利,水肿、泄泻、淋浊,带下。
茯苓:味甘、淡;性平。归心、肺、脾、肾经。利水渗湿,健脾,宁心。用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不宁,惊悸失眠。
苍术:味辛、苦;性温。归脾、胃、肝经。燥湿健脾,祛风散寒,明目。用于湿阻中焦,脘腹胀满,泄泻,水肿,脚气痿蹙,风湿痹痛,风寒感冒,夜盲,眼目昏涩。
白术:味苦、甘;性温。归脾、胃经。健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。
川牛膝:味甘、微苦;性平。归肝、肾经。逐瘀通经,通利关节,利尿通淋。用于经闭症瘕,胞衣不下,跌扑损伤,风湿痹痛,足痿痉挛,尿血血淋等症。
怀牛膝:味苦、酸;性平。归肝、肾经。主治寒湿痿痹、四肢拘挛,膝痛不可屈伸,逐血气,伤热火烂,久服轻身耐老。长于补益肝肾,强腰膝以及活血、饮血下行的作用。
升麻:味辛、甘;性微寒。归肺、脾、大肠、胃经。发表透疹,清热解毒,升阳举陷。主治时气疫疠,头痛寒热,喉痛,口疮,斑疹不透;中气下陷,久泻久痢,脱肛,妇女崩、带,子宫下坠;痈肿疮毒。
枳壳:味苦、辛、酸;性微寒。归脾、胃经。理气宽中,行滞销胀。用于胸胁气滞,胀满疼痛,食积不化,痰饮内停,脏器下垂。
用药原理:
本发明以标本兼治为原则,立方选药。
方中以太子参益气滋阴生津;黄芪以益气固表;太子参配黄芪,补益之效大增,常用治劳倦乏力为效;生地黄清热养阴生津为君药。山萸肉补养肝肾,并能涩精,取“肝肾同源”之意;生山药补脾益肾;共为臣药。川怀牛膝共用,既能补肝肾又能活血散瘀;苍白术健脾利湿;泽泻利湿而泻肾浊;苍术、泽泻善利水渗湿,使湿无所聚,痰无由生,且苍术亦可健脾,泽泻尚可泄热,猪茯苓淡渗利湿,并助山药之健运,与泽泻共泻肾浊,助真阴得复其位共为佐药。升麻升举清阳,畅达气机,枳壳行气消滞,调畅气机,共为使药。诸药合用,健脾益肾,使脾肾互资,和合互助,从而达到降糖目的。
上述发明的配方制得的中药具有以下优点:
1.本发明采用天然食用药材为原料,各组分配比合理,配方中采用生地黄清热生津为君药;山萸肉与生山药补脾益肾共为臣药;川怀牛膝活血散瘀,苍白术、泽泻与猪茯苓搭配利水渗湿,共为佐药;升麻搭配枳壳调畅气机,共为使药;太子参搭配黄芪,使补益之效大增。与现有技术相比,本发明采用更少的药材,达到了更好的治疗效果,降低了治疗费用,并且能有效健脾益肾,降低血糖,效果显著,无毒无副作用。
2.本发明所述药物为丸状,口服,每次4~8丸,3次/日。无苦涩感,使用方便,适合更多的患病人群。
具体实施方式:
以下实施例及实施方式是为了进一步说明本发明,而不是限制本发明。
实施例1:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参125g、山萸肉120g、生山药120g、生地120g、泽泻115g、猪苓115g、茯苓115g、黄芪190g、苍术40g、白术40g、川牛膝115g、怀牛膝115g、升麻25g和枳壳40g。
实施例2:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成太子参135g、山萸肉135g、生山药135g、生地135g、泽泻125g、猪苓125g、茯苓125g、黄芪210g、苍术55g、白术45g、川牛膝125g、怀牛膝125g、升麻40g和枳壳50g。
实施例3:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参130g、山萸肉127g、生山药127g、生地127g、泽泻120g、猪苓120g、茯苓120g、黄芪200g、苍术47g、白术43g、川牛膝120g、怀牛膝120g、升麻30g和枳壳45g。
实施例4:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参127g、山萸肉127g、生山药127g、生地127g、泽泻117g、猪苓118g、茯苓117g、黄芪194g、苍术43g、白术41g、川牛膝117g、怀牛膝117g、升麻27g和枳壳42g。
实施例5:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参128g、山萸肉129g、生山药129g、生地128g、泽泻118g、猪苓119g、茯苓119g、黄芪198g、苍术45g、白术42g、川牛膝118g、怀牛膝118g、升麻28g和枳壳43g。
实施例6:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参132g、山萸肉132g、生山药132g、生地132g、泽泻121g、猪苓121g、茯苓121g、黄芪205g、苍术52g、白术44g、川牛膝121g、怀牛膝121g、升麻32g和枳壳48g。
实施例7:
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下原料药制成:太子参134g、山萸肉130g、生山药130g、生地134 g、泽泻118g、猪苓120g、茯苓120g、黄芪208g、苍术51g、白术43g、川牛膝122g、怀牛膝122g、升麻34g和枳壳49g。
一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,由以下步骤制成:
A.将太子参、山萸肉、生山药、生地、泽泻、猪苓和茯苓放入烘箱,75℃烘干12小时,混合均匀后粉碎成80目细粉备用。
B.将黄芪、苍术、白术、川牛膝、怀牛膝和枳壳加适量的水煎煮三次,第一次煎煮为2小时,第二次煎煮和第三次煎煮均为1小时。煎液合并滤过,滤液浓缩至清膏。
C.将步骤A所制细粉与步骤B所制清膏混合 后挤压制丸,抛光干燥即得。
本发明组方合理、科学,具有生津利湿、补脾益肾、降低血糖的功效,并在临床应用取得了良好的效果,具体试验情况如下:
1.诊断标准
1.1西医诊断标准
糖尿病诊断标准:参照的是中华医学会糖尿病学分会制定的诊断标准,2013版《中国2型糖尿病防治指南》。
(1)糖尿病主要症状(主要包括多饮、多尿、多食及消瘦),且随机(指餐后任意时间点)静脉血糖(VPG)≥11.1mmol/l(200mg/dl);或加上。
(2)空腹(是指未进食超过8小时)静脉血糖(FPG)水平≥7.0mmol/l(126mg/dl);或加上。
(3)口服葡萄糖(75g无水葡萄糖)耐量试验(OGTT)2h静脉血糖(2hPG)≥11.1mmol/l(200mg/dl)。
1.2中医证候诊断标准:
由开封市中医院内分泌科具有中级以上职称临床医师参照2016年由中国中医药出版社出版的《糖尿病诊疗全书》及2007年中华中医药学会《糖尿病中医防治指南》的有关内容,并结合临床协助制定脾肾气虚证标准:
脾肾气虚证:腰酸腰痛,眼睑或下肢水肿,自汗,小便清长或短少,夜尿增多,或五更泄泻,舌淡体胖有齿痕,脉沉迟无力。
1.3 中医症状积分量化标准
参照国家中医药管理局出版的《22个专业95个病种中医诊疗方案》,由开封市中医院内分泌科具有中级以上职称临床大夫对症状进行计分,分别于治疗前后进行计分登记。
2.治疗方案:
共收集符合入选标准的T2DM患者66例。纳入患者按计算机随机数发生器随机分为治疗组和对照组,每组各33例,纳入患者均在基础治疗的前提下。其中治疗组中男性17例,女性16例;年龄46~65岁,平均(53.17±3.22)岁;病程1~13年,平均(9.15±1.74)年。对照组中男性15例,女性18例;年龄在44~70岁,平均(54.88±4.69)岁;病程1~14年,平均(9.48±1.99)年。治疗方法:治疗组给予健脾益肾调糖丸,按本发明要求用药,每次4~8丸,3次/日;对照组给予盐酸二甲双胍缓释片(广东华南药业集团有限公司,国药准字H44020757),每天1次,每次于早餐前口服0.5g。四周为1个疗程,连用三个疗程共12周。对两组患者治疗前后的中医证候疗效、总疗效、临床症状积分、空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、胰高血糖素释放试验、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞分泌指数(HOMA-β)、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)进行统计分析,并分别将两组在治疗2周、4周、8周、12周后的血糖水平标准差(SDBG)、餐后血糖波动幅度(PPGE)、最大血糖波动幅度(LAGE)分别进行统计分析。
3.疗效评价标准:
3.1中医证侯疗效标准由开封市中医院具有中级以上职称的内分泌科临床医师参考国家中医药管理局出版的《22个专业95个病种中医诊疗方案》进行判定。
(1)临床症状及体征明显改善,积分减少≥70%以上视为显效。
(2)临床症状及体征均有好转,积分减少≥30%以上视为有效。
(3)临床症状及体征均无明显改善,甚或加重,积分减少不足30%以上视为无效。
注:按照尼莫地平法计算:疗效指数(n)=[(治疗前积分一治疗后积分)/治疗前积分]×100%
3.2 疾病总疗效判定标准
由开封市中医院具有中级以上职称的内分泌科临床医师参考国家中医药管理局出版的《22个专业95个病种中医诊疗方案》[7]进行判定。
(1)中医临床症状及体征均明显改善,症候积分减少≥70%,FPG及2hPG至正常范围或FPG及2hPG值下降超过治疗前的40%,HbA1C下降至6.2%以下,或下降超过治疗前的30%,以上视为显效。
(2)中医临床症状及体征均有好转,症候积分减少≥30%,FPG及2hPG下降超过治疗前的20%,但未达到显效标准,HbA1C值下降超过治疗前的10%,但未达到显效标准,以上视为有效。
(3)中医临床症状及体征均无明显改善,甚或加重,症候积分减少不足30%,FPG及2hPG无下降,或下降未达到有效标准,HbA1C值无下降,或下降未达到有效标准,以上视为无效。
3.3 安全性评判标准:(采用2003年《中药新药临床研究指导原则》中关于糖尿病的疗效标准)对整个治疗过程中包括治疗后,实验室检查指标异常及不良事件的发生情况,进行综合判断。
(1)1级:安全,无任何不良反应。
(2)2级:比较安全,如有不良反应,不需做任何处理可继续给药。
(3)3级:存在安全问题,有中等程度的不良反应,给予适当处理后可继续用药。
(4)4级:因不良反应中止试验。
3.3结果
治疗组33例中显效10例,有效19例,无效4例,总有效率87.9%;对照组33例中显效8例,有效18例,无效7例,总有效率78.9%;治疗组与对照组比较(P<0.05),治疗组疗效优于对照组。
通过临床观察发现健脾益肾调糖丸能显著改善T2DM患者的临床症状,同时能改善其糖脂代谢紊乱,改善胰岛功能,减轻胰岛素抵抗,降低胰高血糖素及血糖波动度,且在临床观察过程当中未出现任何毒副作用,应用安全。
临床应用12年,效果好,共治疗8600例,基本痊愈2342例,显效2800例,有效3200例,总有效率达97%,与同类药相比有疗效好、费用低等特点。
典型病例1:患者张某某,女66岁,2016年02月27日初诊,2型糖尿病9年,平素口服药物控制血糖(具体不详),血糖控制差,现症见:口干渴,乏力,腰酸痛,眼睑水肿,自汗,纳食欠佳,小便频数,夜尿3~5次,大便偏稀,每日一次,夜眠差。舌淡暗红,苔白腻,舌体胖有齿痕,脉沉迟无力。查空腹今测空腹血糖:12.2mmol/L。糖化血红蛋白:13.93%。中医诊断:消渴病,脾肾气虚证,制定纯中医药治疗方案,给予本发明丸剂口服;2周后患者口干多饮症状减轻,腰酸痛减轻,眼睑水肿消退,测空腹血糖在8~10mmol/L之间;4周后复诊,舌质暗红,苔白稍腻,脉沉细,纳眠较前好,无自汗,小便可,夜尿1次,测空腹血糖降至6~9mmol/L之间;8周复诊,患者转至薄白苔,余基本正常;12周复诊,患者血糖稳定,复查胰岛功能较前明显改善,本发明丸剂,减至维持量服用。
典型病例2:患者冯某某,女,67岁,2017年02月24日就诊。有“2型糖尿病”20年,1周前出现双下肢及颜面水肿,有口干渴,腰膝酸软,乏力,纳食减少,伴有阵发性恶心反胃,无呕吐,夜眠差,夜尿增多,大便溏薄。查空腹血糖9.3mmol/L,糖化血红蛋白:9%。肾功能示:尿素:7.73mmol/L,尿酸:292U/L,肌酐:85umol/L。尿常规示:尿蛋白(+),尿糖(3+),舌质暗红,苔薄白,脉细。中医诊断:消渴病 脾肾气虚证。停口服某自制降糖药物(具体不详),给予中药健脾益肾调糖饮5剂口服,因患者不能耐受汤剂,给予使用本发明丸剂调服;用药1周后口干渴、腰膝酸软症状减轻,纳食较前好,无恶心反胃。测空腹血糖在8~10mmol/L之间;用药2周后乏力症状明显改善,精神好转,眼睑水肿消退,空腹血糖降至7~9mmol/L之间;4周后各不适症状基本消失,空腹血糖7~8mmol/L,餐后2h血糖11~12mmol/L之间,继续服用本丸剂;8周及12周复诊,血糖基本稳定,HbAc7.1%,后电话回访,患者维持用药,空腹血糖6~7mmol/L,餐后2h血糖9~11mmol/L之间,血糖正常。
典型病例3:患者姚某某,女,45岁,诊断于2018年01月24日。有“2型糖尿病”病史16年,现用“盐酸二甲双胍缓释片0.25g 每日2次,口服”控制血糖,平素测空腹血糖在9~13mmol/L间。1月前因劳累出现腰膝酸痛,眼睑水肿,故来诊。现症见:患者神志清,精神欠佳,口干渴、多饮,腰膝酸痛,眼睑水肿,双眼视物模糊,乏力,纳食差,睡眠欠佳,五更泄泻,小便频数,夜尿3~4次。查肾功能正常,测空腹血糖:9.3 mmol/L,糖化血红蛋白:10.96%。中医诊断:消渴病 脾肾气虚证。停服用盐酸二甲双胍缓释片,完善胰岛功能等相关检查。给予中药健脾益肾调糖饮7剂口服,后给予使用本发明丸剂调服;用药2周后精神好转,口干渴、腰膝酸软症状减轻,眼睑水肿消退。测空腹血糖在8~9mmol/L之间;用药4周后乏力症状明显改善,眼睑水肿消退,纳眠、二便可,空腹血糖降至6~7mmol/L之间;8周后复诊,未诉特殊不适,测空腹血糖6~7mmol/L,患者维持用药。
可以理解的是,以上关于本发明的具体描述,仅用于说明本发明而并非受限于本发明实施例所描述的技术方案,本领域的普通技术人员应当理解,仍然可以对本发明进行修改或等同替换,以达到相同的技术效果;只要满足使用需要,都在本发明的保护范围之内。
Claims (6)
1.一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,其特征在于,采用以下中药原料制备而成:太子参125~135g、山萸肉120~135g、生山药120~135g、生地120~135g、泽泻115~125g、猪苓115~125g、茯苓115~125g、黄芪190~210g、苍术40~55g、白术40~45g、川牛膝115~125g、怀牛膝115~125g、升麻25~35g和枳壳40~50g。
2.根据权利要求1所述的一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,其特征在于,采用以下中药原料制备而成:太子参125g、山萸肉120g、生山药120g、生地120g、泽泻115g、猪苓115g、茯苓115g、黄芪190g、苍术40g、白术40g、川牛膝115g、怀牛膝115g、升麻25g和枳壳40g。
3.根据权利要求1所述的一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,其特征在于,采用以下中药原料制备而成:太子参130g、山萸肉127g、生山药127g、生地127g、泽泻120g、猪苓120g、茯苓120g、黄芪200g、苍术47g、白术43g、川牛膝120g、怀牛膝120g、升麻30g和枳壳45g。
4.根据权利要求1所述的一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸,其特征在于,采用以下中药原料制备而成:太子参135g、山萸肉135g、生山药135g、生地135g、泽泻125g、猪苓125g、茯苓125g、黄芪210g、苍术55g、白术45g、川牛膝125g、怀牛膝125g、升麻40g和枳壳50g。
5.权利要求1~4中任一所述的一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸的制备方法,其特征在于,包括以下步骤:
A.将太子参、山萸肉、生山药、生地、泽泻、猪苓和茯苓放入烘箱,75℃烘干12小时,混合均匀后粉碎成80目细粉备用;
B.将黄芪、苍术、白术、川牛膝、怀牛膝、升麻和枳壳加适量的水煎煮三次,煎液合并滤过,滤液浓缩至清膏;
C.将步骤A所制细粉与步骤B所制清膏混合后挤压制丸,抛光干燥即得。
6.根据权利要求5所述的一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸的制备方法,其特征在于:所述煎煮三次中第一次煎煮为2小时,第二次煎煮和第三次煎煮均为1小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811603562.XA CN109498731A (zh) | 2018-12-26 | 2018-12-26 | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811603562.XA CN109498731A (zh) | 2018-12-26 | 2018-12-26 | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109498731A true CN109498731A (zh) | 2019-03-22 |
Family
ID=65755393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811603562.XA Pending CN109498731A (zh) | 2018-12-26 | 2018-12-26 | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109498731A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112451618A (zh) * | 2020-11-10 | 2021-03-09 | 青岛大学附属医院 | 一种治疗糖尿病肾病的中药组合物 |
CN112717050A (zh) * | 2021-02-04 | 2021-04-30 | 北京前望医药科技有限公司 | 一种治疗ⅱ型糖尿病的中药复方制剂 |
-
2018
- 2018-12-26 CN CN201811603562.XA patent/CN109498731A/zh active Pending
Non-Patent Citations (3)
Title |
---|
代珍珍等: "庞国明治疗2型糖尿病肾气虚证临床经验", 《世界中西医结合杂志》 * |
庞国明: "纯中药治疗2型糖尿病临床研究"序贯三法"临床应用", 《中华中医药学会糖尿病分会2017年学术年会暨第十八次中医糖尿病大会论文汇编》 * |
庞国明等: "脾肾气虚血糖高 双补脾肾调糖好", 《中国中医药报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112451618A (zh) * | 2020-11-10 | 2021-03-09 | 青岛大学附属医院 | 一种治疗糖尿病肾病的中药组合物 |
CN112717050A (zh) * | 2021-02-04 | 2021-04-30 | 北京前望医药科技有限公司 | 一种治疗ⅱ型糖尿病的中药复方制剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103735838B (zh) | 一种养肾补肾保健药酒及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN105250723B (zh) | 一种治疗糖尿病的药物 | |
CN108295211A (zh) | 一种治疗糖尿病的药食同源食品组方及其制备方法 | |
CN1899455B (zh) | 一种治疗小儿热型腹泻的外贴膏及制备方法 | |
CN103041360A (zh) | 一种治疗功能性腹泻和肠易激综合征的口服液 | |
CN101125177B (zh) | 治疗糖尿病的醪酒 | |
CN104491342A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN109498731A (zh) | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 | |
CN104083640B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN104367753B (zh) | 一种治疗2型糖尿病的中药组合物 | |
CN104784538B (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
CN103223087A (zh) | 一种治疗糖尿病的食疗组方 | |
CN101199756B (zh) | 一种治疗糖尿病的药物 | |
CN103751558B (zh) | 一种复方降糖丸剂及其制备方法 | |
CN102274396A (zh) | 治疗糖尿病肾病的中药及其制备方法 | |
CN109395045A (zh) | 一种治疗2型糖尿病湿热中阻证的清热化湿调糖丸及其制备方法 | |
CN103223137B (zh) | 一种降血糖的中药制剂 | |
CN105168946A (zh) | 一种治疗糖尿病的中药组合物及其用途 | |
CN105663772B (zh) | 一种治疗糖尿病的药物 | |
CN106902250A (zh) | 一种中西医联合治疗糖尿病的复方药物 | |
CN103721186B (zh) | 一种治疗糖尿病和更年期综合症的药黄酒及其制备方法 | |
CN102366480A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN105381273A (zh) | 一种治疗糖尿病的药物组合物及其用途 | |
CN105770394A (zh) | 一种治疗糖尿病的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |
|
RJ01 | Rejection of invention patent application after publication |